{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:19:40Z","timestamp":1777555180125,"version":"3.51.4"},"reference-count":54,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Black cisgender women in the Southern United States experience disproportionate human immunodeficiency virus (HIV) rates. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool but is underutilized in this population. We assessed PrEP cascade outcomes and correlates among Black women in the Southern United States. Between March and June 2022, we administered a cross-sectional online survey to Black cisgender women residing in the Southern United States who reported unprotected sex in the past 6 months and were negative for HIV by self-report. Participants provided information on sociodemographic characteristics, HIV knowledge, PrEP awareness and use, psychosocial factors, and health care access. We used descriptive statistics and multivariate logistic regression models to describe the sample and assess the correlates of PrEP outcomes, respectively. Participants included 491 Black women, with a mean age of 40.1 years (SD: 17.5); 53% had a college degree or lower, and 79% were single. PrEP awareness was 39.5%, willingness 25.7%, and current use only 5.5%. The factors associated with PrEP awareness included younger age (aOR = 1.02, 95% CI: 1.01\u20131.03), higher education (aOR = 1.68, 95% CI: 1.09\u20132.60), medical trust (aOR = 1.09, 95% CI: 1.03\u20131.15), binge drinking (aOR = 1.77, 95% CI: 1.06\u20132.94), and HIV testing in the past year (aOR = 1.55, 95% CI: 0.98\u20132.45). The PrEP willingness predictors included HIV testing in the past year (aOR = 1.80, 95% CI: 1.11\u20132.90) and HIV worry (aOR = 1.84, 95% CI: 1.09\u20133.09). HIV testing emerged as a key facilitator for both PrEP awareness and willingness, suggesting that testing encounters represent critical opportunities for PrEP integration. PrEP strategies should address both individual-level factors and structural barriers, particularly medical trust within health care systems.<\/jats:p>","DOI":"10.1177\/10872914251399940","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:35:57Z","timestamp":1764063357000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-Exposure Prophylaxis Cascade Outcomes Among Black Cisgender Women in the Southern United States"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-233X","authenticated-orcid":false,"given":"Sylvia","family":"Shangani","sequence":"first","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."},{"name":"Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Acacia R.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivesh","family":"Shourya","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina A.","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M.","family":"Sales","sequence":"additional","affiliation":[{"name":"Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Rodriguez-Diaz","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Center for Disease Control and Prevention. New HIV surveillance report. 2024. Available from: https:\/\/www.cdc.gov\/nchhstp\/director-letters\/cdc-publishes-new-hiv-surveillance-reports.html [Last accessed: September16 24]."},{"key":"e_1_3_2_3_2","unstructured":"Center for Disease Control and Prevention. HIV Diagnoses Deaths and Prevalence. 2024. Available from: https:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-prevalence.html [Last accessed: August12 2024]."},{"key":"e_1_3_2_4_2","unstructured":"Center for Disease Control and Prevention. HIV diagnoses deaths and prevalence: 2025 update. 2025. Available from: https:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-and-prevalence-2025.html"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00395-0"},{"key":"e_1_3_2_6_2","unstructured":"Center for Disease Control and Prevention. HIV surveillance supplemental report: Estimated HIV incidence and prevalence in the United States 2018\u20132022. 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/156513 [Last accessed: 27August 2025]."},{"key":"e_1_3_2_7_2","unstructured":"Center for Disease Control and Prevention. PrEP effectiveness. 2022. Available from: https:\/\/www.cdc.gov\/hiv\/prevention\/prep.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/hiv\/basics\/prep\/prep-effectiveness.html [Last accessed: 8August 2025]."},{"key":"e_1_3_2_8_2","unstructured":"U.S. Public Health Services. Pre-exposure prophylaxis for the prevention of HIV infection in the United States-2021 Update. 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/112360 [Last accessed: 14April 2025]."},{"key":"e_1_3_2_9_2","unstructured":"Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention"},{"key":"e_1_3_2_10_2","unstructured":"Gilead Sciences. Yeztugo\u00ae (Lenacapavir) is now the first and only FDA-approved HIV prevention option offering 6 months of protection. GILEAD; 2025. Available from: https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection [Last accessed: October30 2025]."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00056-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001385"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ664"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02843-z"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2067-8"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03853-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2020.1720297"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-023-02712-5"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-023-01729-9"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0142"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2023.05.009"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10410236.2022.2145781"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0201"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/17455057221103098"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2018.08.004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-021-01020-9"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2025.0043"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00447-4"},{"key":"e_1_3_2_31_2","unstructured":"Kaiser Family Foundation. The impact of HIV on Black people in the United States. 2024. Available from: https:\/\/www.kff.org\/hivaids\/fact-sheet\/the-impact-of-hiv-on-black-people-in-the-united-states\/ [Last accessed: May30 2025]."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04491-z"},{"issue":"1","key":"e_1_3_2_33_2","first-page":"51","article-title":"African American women\u2019s current knowledge, perceptions, and willingness of PrEP use for HIV prevention in the South","volume":"11","author":"Troutman J","year":"2021","unstructured":"Troutman J, , Ingram LA, , Gaddist B, et al. African American women\u2019s current knowledge, perceptions, and willingness of PrEP use for HIV prevention in the South. J Healthc Sci Humanit, 2021; 11(1):51\u201372.","journal-title":"J Healthc Sci Humanit"},{"key":"e_1_3_2_34_2","unstructured":"Center for Disease Control and Prevention. Clinical guidance for PrEP. HIV Nexus. Updated March 5. 2025. Available from: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html [Last accessed: May20 2025]."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-019-01470-7"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2003.09.041"},{"issue":"2","key":"e_1_3_2_37_2","first-page":"185","article-title":"The pre-exposure prophylaxis (PrEP) stigma scale: Preliminary findings from a pilot study","volume":"11","author":"Klein H","year":"2019","unstructured":"Klein H, , Washington TA. The pre-exposure prophylaxis (PrEP) stigma scale: Preliminary findings from a pilot study. Int Public Health J, 2019; 11(2):185\u2013195.","journal-title":"Int Public Health J"},{"key":"e_1_3_2_38_2","unstructured":"National Institute on Alcohol Abuse and Alcoholism. What is binge drinking?. 2021. Available from: https:\/\/www.niaaa.nih.gov\/publications\/brochures-and-fact-sheets\/binge-drinking [Last accessed: 14October 2025]."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03107-6"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/1524839912470453"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0054"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2016.1261969"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-022-00617-x"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234821"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2021.1916870"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2283-2"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002377"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002974"},{"key":"e_1_3_2_49_2","unstructured":"Kaiser Family Foundation. Status of State Medicaid expansion decisions: Interactive map. 2024. Available from: https:\/\/www.kff.org\/affordable-care-act\/issue-brief\/status-of-state-medicaid-expansion-decisions-interactive-map\/ [Last accessed: 14October 2025]."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2019.305452"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08122-6"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000001762"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0385-0"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0189"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0300"}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914251399940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914251399940","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914251399940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:09:04Z","timestamp":1777399744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914251399940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10872914251399940"],"URL":"https:\/\/doi.org\/10.1177\/10872914251399940","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}